

Virax Biolabs inks commercial supply agreement with Fosun Diagnostics covering six Southeast Asian markets

July 10, 2026 | News

Virax will supply ImmuneSelect immune profiling products, including ELISpot assay plates



Virax Biolabs has announced that its wholly owned subsidiary, Virax Biolabs (UK) has entered into an exclusive multi-country commercial supply agreement with Fosun Diagnostics for the company's ImmuneSelect research-use immune profiling product line.

The agreement covers six Southeast Asian markets, including Thailand, Vietnam, Indonesia, the Philippines, Singapore and Malaysia, and establishes a framework for immediate product supply under purchase orders, supporting near-term potential revenue opportunities and regional commercial expansion.

ImmuneSelect is Virax's commercially available research-use-only (RUO) immune profiling product line and is distinct from ViraxImmune™, the company's in-development diagnostic platform currently progressing through clinical and regulatory development.

Virax will supply ImmuneSelect immune profiling products, including ELISpot assay plates used to measure cellular immune responses, to Fosun Diagnostics under purchase orders, enabling immediate commercial execution. Pricing includes structured volume-based tiers reflecting scalable commercial economics across the ASEAN region.

The initial focus is tuberculosis-related research applications in Thailand, where Fosun has identified near-term customer demand and is progressing initial evaluation activity through Fosun Pharma's regional network, with rollout potential across Vietnam, Indonesia, the Philippines, Singapore and Malaysia.